ADA3: a novel target for HPV16 E6 oncoprotein
ADA3: a novel target for HPV16 E6 oncoprotein
批准号:
7086808
负责人:
VIMLA BAND
金额:
$23.32万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2007-10-31
关键词:
acyltransferaseapoptosiscell differentiationcell proliferationepitheliomagene induction /repressiongenetic transcriptionhuman papillomavirusneoplasm /cancer geneticsneoplastic transformationoncoproteinsprotein structure functionretinoid binding proteinstranscription factortumor suppressor genesvirus related neoplasm /canceryeast two hybrid system
中文摘要
描述(由申请人提供):人类癌起源于正常上皮细胞,通过肿瘤抑制检查点的渐进式放松。HPV E6癌基因可以显著地使乳腺上皮细胞永生,否则乳腺上皮细胞会表现出有限的寿命,这为鉴定上皮细胞转化过程中失活的肿瘤抑制途径提供了一种实用的方法。该模型揭示了p53功能失活的关键作用;然而,选择性地消除p53功能并不能导致有效的永生化,这表明了其他途径的作用。我们已经确定了酵母转录辅激活子yADA3的人类同源物,作为一个新的E6靶点。yADA3是连接转录激活因子与组蛋白乙酰化和基础转录机制的辅激活因子复合物的关键成分。重组哺乳动物核受体介导的酵母转录,揭示了对yADA3及其相关蛋白yADA2和yGCN5的需求。基于这些研究,以及hADA3选择性结合高危HPV E6蛋白和永生化E6突变体,我们假设hADA3参与维持上皮细胞正常状态的基因的转录调控。由于hADA3与HPV E6的相互作用或通过其他方式,hADA3功能的丧失或失调可能是HPV相关癌症和其他癌症的重要致癌机制。为了验证我们的假设,我们将生成针对人类ADA3和ADA2的抗体,并检测它们的表达,并确定含有hada3的组蛋白乙酰化酶复合物的存在及其参与上皮细胞中类视黄醇受体介导的基因转录。然后,我们将定义ADA3的结构域,介导其与活化的类视黄醛受体和组蛋白乙酰化酶复合物的物理和功能相互作用。我们将研究E6是否通过取代结合伙伴或ADA3降解来灭活ADA3功能。最后,我们将确定ADA3在介导细胞分化和生长抑制功能中的潜在作用,并评估ADA3显性阴性突变体诱导永生化的潜力。这些研究的成功结果应该确定一种新的肿瘤抑制途径,其成分可能为癌症的早期诊断提供新的标志物,并为开发合理的治疗方法提供靶点。
英文摘要
DESCRIPTION (provided by applicant): Human carcinomas arise from normal epithelial cells through progressive relaxation of tumor suppressor checkpoints. HPV E6 oncogene can dominantly immortalize mammary epithelial cells, which otherwise exhibit a finite life span, providing a practical approach to identify tumor suppressor pathways inactivated during transformation of epithelial cells. This model revealed a crucial role for inactivation of p53 functions; however, selective elimination of p53 function did not lead to efficient immortalization, indicating the role of additional pathways. We have identified the human homologue of yeast transcriptional coactivator yADA3, as a novel E6 target. yADA3 is a critical component of coactivator complexes that link transcriptional activators to histone acetylation and basal transcriptional machinery. Reconstitution of mammalian nuclear receptor-mediated transcription in yeast revealed a requirement for yADA3, and associated proteins, yADA2 and yGCN5. Based on these studies, and selective binding of hADA3 to high-risk HPV E6 proteins and immortalizing E6 mutants, we hypothesize that hADA3 participates in transcriptional regulation of genes that maintain the normal state of epithelial cells. Loss or deregulation of hADA3 function, due to its interaction with HPV E6 or by other means, is likely to represent an important oncogenic mechanism in HPV-associated and other cancers. To address our hypotheses, we will generate antibodies to human ADA3 and ADA2, and examine their expression, and establish the presence of hADA3-containing histone acetylase complexes and their involvement in retinoid receptor-mediated gene transcription in epithelial cells. We will then define the domains of ADA3 that mediate its physical and functional interactions with activated retinoid receptors and histone acetylase complexes. We will examine whether E6 inactivates ADA3 function by displacement of binding partners or ADA3 degradation. Finally, we will determine the potential role of ADA3 in mediating cell differentiation and growth inhibitory functions, and assess the potential of dominant-negative ADA3 mutants to induce immortalization. Successful outcome of these studies should identify a novel tumor suppressor pathway whose components may provide new markers for early diagnosis of carcinomas, and targets for development of rational therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer
-
批准号:10474522
-
项目类别:
-
资助金额:$7.68万
-
财政年份:2021
-
负责人:VIMLA BAND
-
依托单位:
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer
-
批准号:10294847
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2021
-
负责人:VIMLA BAND
-
依托单位:
Ecdysoneless, A Novel Regulator of Androgen Receptor
-
批准号:9809834
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2019
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8775947
-
项目类别:
-
资助金额:$4.94万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8616349
-
项目类别:
-
资助金额:$29.89万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8448016
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8825337
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8115725
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
Ecd as a regulator of cell cycle and breast oncogenesis
-
批准号:8231335
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7554732
-
项目类别:
-
资助金额:$20.14万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7323606
-
项目类别:
-
资助金额:$6.9万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6803610
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6521549
-
项目类别:
-
资助金额:$28.81万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7892414
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:6548000
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:7554861
-
项目类别:
-
资助金额:$9.7万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:8109367
-
项目类别:
-
资助金额:$25.28万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
ADA3: a novel target for HPV16 E6 oncoprotein
-
批准号:6916532
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53 function
-
批准号:6647144
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
A novel regulator of p53
-
批准号:7491822
-
项目类别:
-
资助金额:$25.31万
-
财政年份:2002
-
负责人:VIMLA BAND
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: